BHB: A simple knowledge-based scoring function to improve the efficiency of database screening

Journal of Chemical Information and Computer Sciences

Volumn 43, Issue 4, 2003, Pages 1316-1327

  Feher, Miklos ^a,b   Deretey, Eugen ^a   Roy, Samir ^a  

^a Signalgene Inc Canada   (Canada)

^b NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; COMPLEXATION; DATABASE SYSTEMS; HYDROGEN BONDS; THERMODYNAMICS;

LIGANDS;

DRUG PRODUCTS;

EID: 0042199035     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci030006i     Document Type: Article

References (51)

1. Bissantz, C.; Folkers, G.; Rognan, D. Protein-Based Virtual Screening of Chemical Databases. 1. Evaluation of Different Docking/Scoring Combinations. J. Med. Chem. 2000, 43, 4759-4767.
2. Taylor, R. D.; Jewsbury, P. J.; Essex, J. W. A review of protein-small molecule docking methods. J. Comput.-Aided Mol. Des. 2002, 16, 151-166.
3. Stahl, M.; Rarey, M. Detailed analysis of scoring functions for virtual screening. J. Med. Chem. 2001, 44, 1035-1042.
4. Charifson, P. S.; Corkery, J. J.; Murcko, M. A.; Walters, W. P. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J. Med. Chem. 1999, 42, 5100-5109.
5. Nicodeme. P.; Didier, R. ConsDock: A New Program for the Consensus Analysis of Protein-Ligand Interactions. Proteins 2002, 47, 521-533.
6. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-45.
7. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295, 337-356.
8. Muegge, I.; Martin, Y. C. A general and fast scoring function for protein-ligand interactions; a simplified potential approach. J. Med. Chem. 1999, 42, 791-804.
9. Rognan, D.; Lauemoller, S. L.; Holm, A.; Buus, S.; Tschinke, V. Predicting binding affinities of protein ligands from three-dimensional models: application to peptide binding to class I major histocompatibility proteins. J. Med. Chem. 1999, 42, 4650-4658.
10. Böhm, H. J. The development of a single empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput.-Aided Mol. Des. 1994, 8, 243-256.
11. Clark, R. D.; Strizev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graph. Model. 2002, 20, 281-295.
12. Wang, R.; Wang, S. How Does Consensus Scoring Work for Virtual Library Screening? An Idealized Computer Experiment. J. Chem. Inf. Comput. Sci. 2001, 41, 1422-1426.
13. Jones, G.; Wilett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
14. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
15. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
16. Glide 2.0. Schrodinger Inc.: Portland, OR, 2002.
17. Abagyan, R.; Totrov, M. High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 2001, 5, 375-82.
18. Jones, G.; Willett, P.; Glen, R. C. Moelcular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation. J. Mol. Biol. 1995, 245, 43-53.
19. Nissink, J. W. M.; Murray, C.; Hartshorn, M.; Verdonk, M. L.; Cole, J. C.; Taylor, R. A New Test Set for Validating Predictions of Protein-Ligand Interactions. Proteins 2002, 49, 457-71.
20. GOLD, versions 1.2 and 2.0. Cambridge Crystallographic Data Centre: Cambridge, U.K., 2002.
21. Stahl, M. Modifications of the scoring function in FlexX for virtual screening applications. Perspect. Drug Discovery Des. 2000, 20, 83-98.
22. Molecular Operating Environment, version 2002.03. Chemical Computing Group Inc.: Montreal, PQ.
23. ACD logD suite, version 6.00. Advanced Chemistry Development Inc.: Toronto, ON.
24. Halgren, T. A. The Merck Molecular Force Field. I. Basis, Form, Scope, Parametrization, and Performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
25. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical Treatment of Solvation for Molecular Mechanics and Dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
26. Qiu, D.; Shenkin, P. S.; Hollinger, F. P.; Still, W. C. The GB/SA Continuum Model for Solvation. A Fast Analytical Method for the Calculation of Approximate Born Radii. J. Phys. Chem. A 1997, 101, 3005-3114.
27. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucl. Acid Res. 2000, 28, 235-242.
28. Stahl, M.; Böhm, H.-J. Development of filter functions for protein-ligand docking. J. Mol. Graph. Model. 1998, 16, 121-132.
29. Stickle, D. F.; Presta, L. G.; Dill, K. A.; Rose, G. D. Hydrogen bonding in globular proteins. J. Mol. Biol. 1992, 226, 1143-1159.
30. Schmidt, J. M.; Mercure, J. A.; Feher, M.; Dunn-Dufault, R.; Peter, M. G.; Redden, P. R. De Novo Design, Synthesis and Evaluation of Novel Non-Steroidal High Affinity Ligands for the Estrogen Receptor. J. Med. Chem. 2003, 46, 1408-1418.
31. Hindle, S. A.; Rarey, M.; Buning, C.; Lengauer, T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des. 2002, 16, 129-149.
32. Pearlman, D. A.; Charifson, P. S. Improved Scoring of Ligand-Protein Interactions Using OWFEG Energy Grids. J. Med. Chem. 2001, 44, 502-511.
33. http://www.schrodinger.com/docs/impact2.0/pdf/tech_notes/tech_notes.pdf, (last accessed 16.10.2002).
34. The decoy set was kindly provided by Dr. Tom Halgren, Schrodinger Inc., for the evaluation of the Glide program and its comparison with other approaches.
35. Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J. A. The estradiol pharmacophore: Ligand structure - estrogen receptor binding affinity relationships and a model for the estrogen receptor binding site. Steroids 1997, 62, 268-298.
36. Singh, S. M.; Gauthier, S.; Labrie, F. Androgen Receptor Anatagonists (Antiandrogens): Structure Activity Relationships. Curr. Med. Chem. 2000, 7, 211-247.
37. Sintchak, M. D.; Nimmesgern, E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000, 47, 163-184.
38. Bauer, E. R. S.; Daxenberger, A.; Petri, T.; Sauerwein, H.; Meyer, H. H. D. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. Acta Pathol. Microbiol. Immunol. Scand. 2000, 108, 838-846.
39. Hardman, J. G., Limbird, L. E., Eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th ed.; McGraw-Hill Medical: New York, 2001; Chapter 58, pp 1597-1629.
40. Harris, H. A.; Bapat, A. R.; Gonder, D. S.; Frail, D. E. The ligand binding profiles of estrogen receptors alpha and beta are species dependent. Steroids 2002, 67, 379-384.
41. McKimm-Breschkin, J. L.; Sahasrabudhe, A.; Blick, T. J.; McDonald, M.; Colman, P. M.; Hart, G. J.; Bethell, R. C.; Varghese, J. N. Mutations in a Conserved Residue in the Influenza virus Neuraminidase Active Site Decrease Sensitivity to Neu5Ac2en-derived Inhibitors. J. Virol. 1998, 72, 2456-2462.
42. Taylor, N. R.; Cleasby, A.; Singh, O.; Skarzynski, T.; Wonacott, A. J.; Smith, P. W.; Sollis, S. L.; Howes, P. D.; Cherry, P. C.; Bethell, R.; Colman, P.; Varghese, J. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J. Med. Chem. 1998, 41, 798-807.
43. Vermersch, P. S.; Tesmer, J. G.; Lemon, D. D.; Quiocho, F. A. A Pro to Gly Mutation in the Arabinose-binding Protein Enhances and Alters Specificity. J. Biol. Chem. 1990, 265, 16592-16603.
44. Champness, J. N.; Bennett, M. S.; Wien, F.; Visse, R.; Summers, W. C.; Herdewijn, P.; Clerq, E.; Ostrowski, T.; Jarvest, R. L.; Sanderson, M. R. Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands. Proteins 1998, 32, 350-361.
45. Hardcastle, I. R.; Golding, B. T.; Griffin, R. J. Designing Inhibitors of Cyclin-Dependent Kinases. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 325-348.
46. Davis, S. T.; Benson, B. G.; Bramson, H. N.; Chapman, D. E.; Dickerson, S. H.; Dold, K. M.; Eberwein, D. J.; Edelstein, M.; Frye, S. V.; Gamp, R. T., Jr.; Griffin, R. J.; Harris, P. A.; Hassell, A. M.; Holmes, W. D.; Hunter, R. N.; Knick, V. B.; Lackey, K.; Lovejoy, B.; Luzzio, M. J.; Murray, D.; Parker, P.; Rocque, W. J.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001, 291, 134-137.
47. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. 2001, 44, 4339-58.
48. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.; Hofmann, G. A.; Sheldrake, P. L.; McDonnel, P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Regulation of Stress-Induced Cytokine Production by Pyridinylimidazoles; Inhibition of CSBP Kinase. Bioorg. Med. Chem. 1997, 5, 49-64.
49. Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger, S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C. F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S.; O'Neill, E. A.; Orevillo, C. J.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Visco, D. M.; O'Keefe, S. J. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 1999, 42, 2180-2190.
50. Thurmond, R. L.; Wadsworth, S. A.; Schafer, P. H.; Zivin, R. A.; Siekierka, J. J. Kinetics of small molecule inhibitor binding to p38 kinase. Eur. J. Biochem. 2001, 268, 5747-5754.
51. Adams, J. L.; Boehm, J. C.; Gallagher, T. F.; Kassis, S.; Webb, E. F.; Hall, R.; Sorenson, M.; Garigipati, R.; Griswold, D. E.; Lee, J. C. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg. Med. Chem. Lett. 2001, 11, 2867-2870.